Animal models for anti-angiogenic therapy in endometriosis

Journal of Reproductive Immunology

Volumn 97, Issue 1, 2013, Pages 85-94

  Edwards, Andrew K ^a   Nakamura, Diane S ^a   Virani, Sophia ^a   Wessels, Jocelyn M ^b   Tayade, Chandrakant ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Anti angiogenic therapy; Endometriosis; Endothelial progenitor cells; Stromal cell derived factor 1; Thombospondin 1

Indexed keywords

STROMAL CELL DERIVED FACTOR 1; THROMBOSPONDIN 1;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; ENDOMETRIOSIS; ENDOTHELIAL PROGENITOR CELL; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CHEMOKINE CXCL12; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES;

EID: 84874511576     PISSN: 01650378     EISSN: 18727603     Source Type: Journal    
DOI: 10.1016/j.jri.2012.10.012     Document Type: Article

References (115)

1. Adams J.C. Thrombospondins: multifunctional regulators of cell interactions. Annu. Rev. Cell Dev. Biol. 2001, 17:25-51.
2. Aiuti A., Webb I.J., Bleul C., Springer T., Gutierrez-Ramos J.C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med. 1997, 185:111-120.
3. Alfaro L.A., Dick S.A., Siegel A.L., Anonuevo A.S., McNagny K.M., Megeney L.A., Cornelison D.D., Rossi F.M. CD34 promotes satellite cell motility and entry into proliferation to facilitate efficient skeletal muscle regeneration. Stem Cells 2011, 29:2030-2041.
4. Anderson J.C., Grammer J.R., Wang W., Nabors L.B., Henkin J., Stewart J.E., Gladson C.L. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol. Ther. 2007, 6:454-462.
5. Aoki D., Katsuki Y., Shimizu A., Kakinuma C., Nozawa S. Successful heterotransplantation of human endometrium in SCID mice. Obstet. Gynecol. 1994, 83:220-228.
6. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
7. Becker C.M., Sampson D.A., Short S.M., Javaherian K., Folkman J., D'Amato R.J. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil. Steril. 2006, 85:71-77.
8. Becker C.M., Beaudry P., Funakoshi T., Benny O., Zaslavsky A., Zurakowski D., Folkman J., D'Amato R.J., Ryeom S. Circulating endothelial progenitor cells are up-regulated in a mouse model of endometriosis. Am. J. Pathol. 2011, 178:1782-1791.
9. Becker C.M., Rohwer N., Funakoshi T., Cramer T., Bernhardt W., Birsner A., Folkman J., D'Amato R.J. 2-Methoxyestradiol Inhibits hypoxia-inducible factor-1α and suppresses growth of lesions in a mouse model of endometriosis. Am. J. Pathol. 2008, 172:534-544.
10. Becker C.M., Sampson D.A., Rupnick M.A., Rohan R.M., Efstathiou J.A., Short S.M., Taylor G.A., Folkman J., D'Amato R.J. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil. Steril. 2005, 84(Suppl. 2):1144-1155.
11. Becker C.M., Wright R.D., Satchi-Fainaro R., Funakoshi T., Folkman J., Kung A.L., D'Amato R.J. A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am. J. Pathol. 2006, 168:2074-2084.
12. Beltrami A.P., Barlucchi L., Torella D., Baker M., Limana F., Chimenti S., Kasahara H., Rota M., Musso E., Urbanek K., Leri A., Kajstura J., Nadal-Ginard B., Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003, 114:763-776.
13. Bergers G., Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro. Oncol. 2005, 7:452-464.
14. Bulun S.E. Mechanisms of disease: endometriosis. N. Engl. J. Med. 2009, 360:268-279.
15. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., Penfold M.E., Sunshine M.J., Littman D.R., Kuo C.J., Wei K., McMaster B.E., Wright K., Howard M.C., Schall T.J. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203:2201-2213.
16. Burri P.H., Hlushchuk R., Djonov V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev. Dyn. 2004, 231:474-488.
17. Butler J.M., Guthrie S.M., Koc M., Afzal A., Caballero S., Brooks H.L., Mames R.N., Segal M.S., Grant M.B., Scott E.W. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J. Clin. Invest. 2005, 115:86-93.
18. Camargo F.D., Green R., Capetanaki Y., Jackson K.A., Goodell M.A. Single hematopoietic stem cells generate skeletal muscle through myeloid intermediates. Nat. Med. 2003, 9:1520-1527.
19. Campbell N.E., Greenaway J., Henkin J., Moorehead R.A., Petrik J. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 2010, 12:275-283.
20. Capobianco A., Monno A., Cottone L., Venneri M.A., Biziato D., Di Puppo F., Ferrari S., De Palma M., Manfredi A.A., Rovere-Querini P. Proangiogenic Tie2(+) macrophages infiltrate human and murine endometriotic lesions and dictate their growth in a mouse model of the disease. Am. J. Pathol. 2011, 179:2651-2659.
21. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
22. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
23. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
24. Chen H., Herndon M.E., Lawler J. The cell biology of thrombospondin-1. Matrix Biol. 2000, 19:597-614.
25. Cho S.H., Choi Y.S., Jeon Y.E., Im K.J., Choi Y.M., Yim S.Y., Kim H.Y., Seo S.K., Lee B.S. Expression of vascular endothelial growth factor (VEGF) and its soluble receptor-1 in endometriosis. Microvasc. Res. 2012.
26. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 2010, 10:505-514.
27. Crosby J.R., Kaminski W.E., Schatteman G., Martin P.J., Raines E.W., Seifert R.A., Bowen-Pope D.F. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ. Res. 2000, 87:728-730.
28. Dabrosin C., Gyorffy S., Margetts P., Ross C., Gauldie J. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am. J. Pathol. 2002, 161:909-918.
29. Dar A., Goichberg P., Shinder V., Kalinkovich A., Kollet O., Netzer N., Margalit R., Zsak M., Nagler A., Hardan I., Resnick I., Rot A., Lapidot T. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat. Immunol. 2005, 6:1038-1046.
30. Delgado-Rosas F., Gomez R., Ferrero H., Gaytan1 F., Garcia-Velasco J., Simon C., Pellicer A. The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis. Reproduction 2011, 142:745-755.
31. Dogan E., Saygili U., Posaci C., Tuna B., Caliskan S., Altunyurt S., Saatli B. Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertil. Steril. 2004, 82:1115-1120.
32. Domanska U.M., Kruizinga R.C., Nagengast W.B., Timmer-Bosscha H., Huls G., de Vries E.G., Walenkamp A.M. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur. J. Cancer 2012.
33. Donmez G., Sullu Y., Baris S., Yildiz L., Aydin O., Karagoz F., Kandemir B. Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol. Res. Pract. 2009, 205:854-857.
34. Drew E., Merkens H., Chelliah S., Doyonnas R., McNagny K.M. CD34 is a specific marker of mature murine mast cells. Exp. Hematol. 2002, 30:1211-1218.
35. Ebbinghaus S., Hussain M., Tannir N., Gordon M., Desai A.A., Knight R.A., Humerickhouse R.A., Qian J., Gordon G.B., Figlin R. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin. Cancer Res. 2007, 13:6689-6695.
36. Endrich B., Asaishi K., Gotz A., Melbmer K. Technical report - A new chamber technique for microvascular studies in unanesthetized hamsters. Res. Exp. Med. 1980, 177:125-134.
37. Eskenazi B., Warner M.L. Epidemiology of endometriosis. Obstet. Gynecol. Clin. North Am. 1997, 24:235-258.
38. Feng D., Welker S., Korbel C., Rudzitis-Auth J., Menger M.D., Montenarh M., Laschke M.W. Protein kinase CK2 is a regulator of angiogenesis in endometriotic lesions. Angiogenesis 2012, 15:243-252.
39. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3:391-400.
40. Flores I., Rivera E., Ruiz L.A., Santiago O.I., Vernon M.W., Appleyard C.B. Molecular profiling of experimental endometriosis identified gene expression patterns in common with human disease. Fertil. Steril. 2007, 87:1180-1199.
41. Fujii E.Y., Nakayama M., Nakagawa A. Concentrations of receptor for advanced glycation end products, VEGF and CML in plasma, follicular fluid, and peritoneal fluid in women with and without endometriosis. Reprod. Sci. 2008, 15:1066-1074.
42. Furuya M., Suyama T., Usui H., Kasuya Y., Nishiyama M., Tanaka N., Ishiwata I., Nagai Y., Shozu M., Kimura S. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum. Pathol. 2007, 38:1676-1687.
43. Garside S.A., Henkin J., Morris K.D., Norvell S.M., Thomas F.H., Fraser H.M. A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early-antral follicles in vivo. Endocrinology 2010, 151:5905-5915.
44. Giudice L.C. Clinical practice. Endometriosis. N. Engl. J. Med. 2010, 362:2389-2398.
45. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., Bouck N.P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:6624.
46. Gordon M.S., Mendelson D., Carr R., Knight R.A., Humerickhouse R.A., Iannone M., Stopeck A.T. A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 2008, 113:3420-3429.
47. Greenaway J., Henkin J., Lawler J., Moorehead R., Petrik J. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol. Cancer Ther. 2009, 8:64-74.
48. Greenaway J., Lawler J., Moorehead R., Bornstein P., Lamarre J., Petrik J. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J. Cell. Physiol. 2007, 210:807-818.
49. Groothuis P.G., Dassen H.H., Romano A., Punyadeera C. Estrogen and the endometrium: lessons learned from gene expression profiling in rodents and human. Hum. Reprod. Update 2007, 13:405-417.
50. Grummer R. Animal models in endometriosis research. Hum. Reprod. Update 2006, 12:641-649.
51. Guo N., Krutzsch H.C., Inman J.K., Roberts D.D. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 1997, 57:1735.
52. Guo S.W. Recurrence of endometriosis and its control. Hum. Reprod. Update 2009, 15:441-461.
53. Hall J.M., Korach K.S. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis. Mol. Carcinog. 2012.
54. Haviv F., Bradley M.F., Kalvin D.M., Schneider A.J., Davidson D.J., Majest S.M., McKay L.M., Catherine J., Bell R.L., Nguyen B. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J. Med. Chem. 2005, 48:2838-2846.
55. Henkin J., Volpert O.V. Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. Expert Opin. Ther. Targets 2011, 1-18.
56. Hur J., Yoon C.H., Kim H.S., Choi J.H., Kang H.J., Hwang K.K., Oh B.H., Lee M.M., Park Y.B. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler. Thromb. Vasc. Biol. 2004, 24:288-293.
57. Hur S.E., Lee J.Y., Moon H.S., Chung H.W. Angiopoietin-1, angiopoietin-2 and Tie-2 expression in eutopic endometrium in advanced endometriosis. Mol. Hum. Reprod. 2006, 12:421-426.
58. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
59. Jiang H.Q., Li Y.L., Zou J. Effect of recombinant human endostatin on endometriosis in mice. Chin. Med. J. (Engl.) 2007, 120:1241-1246.
60. Katayama H., Katayama T., Uematsu K., Hiratsuka M., Kiyomura M., Shimizu Y., Sugita A., Ito M. Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model. Hum. Reprod. 2010, 25:2851-2858.
61. Kaur S., Martin-Manso G., Pendrak M.L., Garfield S.H., Isenberg J.S., Roberts D.D. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J. Biol. Chem. 2010, 285:38923-38932.
62. Klauber N., Rohan R.M., Flynn E., D'amato R.J. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat. Med. 1997, 3:443-446.
63. Kopp H., Hooper A.T., Broekman M.J., Avecilla S.T., Petit I., Luo M., Milde T., Ramos C.A., Zhang F., Kopp T. Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J. Clin. Invest. 2006, 116:3277.
64. Kopp H.G., Patel S., Brucher B., Hartmann J.T. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. Am. J. Clin. Derm. 2008, 9:207-217.
65. Kopp H.G., Ramos C.A., Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr. Opin. Hematol. 2006, 13:175-181.
66. Korbel C., Menger M.D., Laschke M.W. Size and spatial orientation of uterine tissue transplants on the peritoneum crucially determine the growth and cyst formation of endometriosis-like lesions in mice. Hum. Reprod. 2010, 25:2551-2558.
67. Krause D., Ito T., Fackler M., Smith O., Collector M., Sharkis S., May W.S. Characterization of murine CD34, a marker for hematopoietic progenitor and stem cells. Blood 1994, 84:691-701.
68. Laschke M.W., Schwender C., Scheuer C., Vollmar B., Menger M.D. Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo. Hum. Reprod. 2008, 23:2308-2318.
69. Laschke M., Elitzsch A., Scheuer C., Holstein J., Vollmar B., Menger M. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br. J. Pharmacol. 2006, 149:137-144.
70. Laschke M.W., Elitzsch A., Vollmar B., Menger M.D. In vivo analysis of angiogenesis in endometriosis-like lesions by intravital fluorescence microscopy. Fertil. Steril. 2005, 84(Suppl. 2):1199-1209.
71. Laschke M.W., Giebels C., Menger M.D. Vasculogenesis: a new piece of the endometriosis puzzle. Hum. Reprod. Update 2011, 17:628-636.
72. Laschke M.W., Giebels C., Nickels R.M., Scheuer C., Menger M.D. Endothelial progenitor cells contribute to the vascularization of endometriotic lesions. Am. J. Pathol. 2011, 178:442-450.
73. Laschke M.W., Menger M.D. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum. Reprod. Update 2007, 13:331-342.
74. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell. Mol. Med. 2002, 6:1-12.
75. Lawler J. The functions of thrombospondin-1 and -2. Curr. Opin. Cell Biol. 2000, 12:634-640.
76. Lawler J., Hynes R.O. The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J. Cell Biol. 1986, 103:1635-1648.
77. Levoye A., Balabanian K., Baleux F., Bachelerie F., Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113:6085-6093.
78. Levy A.R., Osenenko K.M., Lozano-Ortega G., Sambrook R., Jeddi M., Belisle S., Reid R.L. Economic burden of surgically confirmed endometriosis in Canada. J. Obstet. Gynaecol. Can. 2011, 33:830-837.
79. Lin Y., Weisdorf D.J., Solovey A., Hebbel R.P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 2000, 105:71-77.
80. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7:1194-1201.
81. Ma J., Ge J., Zhang S., Sun A., Shen J., Chen L., Wang K., Zou Y. Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res. Cardiol. 2005, 100:217-223.
82. Machado D.E., Berardo P.T., Landgraf R.G., Fernandes P.D., Palmero C., Alves L.M., Abrao M.S., Nasciutti L.E. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model. Fertil. Steril. 2010, 93:2674-2679.
83. Markovic S.N., Suman V.J., Rao R.A., Ingle J.N., Kaur J.S., Erickson L.A., Pitot H.C., Croghan G.A., McWilliams R.R., Merchan J. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am. J. Clin. Oncol. 2007, 30:303.
84. Matalliotakis I., Goumenou A., Koumantakis G., Neonaki M., Koumantakis E., Dionyssopoulou E., Athanassakis I., Vassiliadis S. Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines. Int. Immunopharmacol. 2003, 3:81-89.
85. Matsuzaki S., Canis M., Vaurs-Barriere C., Boespflug-Tanguy O., Dastugue B., Mage G. DNA microarray analysis of gene expression in eutopic endometrium from patients with deep endometriosis using laser capture microdissection. Fertil. Steril. 2005, 84(Suppl. 2):1180-1190.
86. McLaren J., Prentice A., Charnock-Jones D., Smith S. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum. Reprod. 1996, 11:220-223.
87. Miao W.M., Seng W.L., Duquette M., Lawler P., Laus C., Lawler J. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res. 2001, 61:7830-7839.
88. Monckedieck V., Sannecke C., Husen B., Kumbartski M., Kimmig R., Totsch M., Winterhager E., Grummer R. Progestins inhibit expression of MMPs and of angiogenic factors in human ectopic endometrial lesions in a mouse model. Mol. Hum. Reprod. 2009, 15:633-643.
89. Murasawa S., Asahara T. Endothelial progenitor cells for vasculogenesis. Physiology (Bethesda) 2005, 20:36-42.
90. Nakamura D.S., Edwards A.K., Virani S., Thomas R., Tayade C. Thrombospondin-1 mimetic peptide ABT-898 affects neovascularization and survival of human endometriotic lesions in a mouse model. Am. J. Pathol. 2012, 181:570-582.
91. Nap A.W., Griffioen A.W., Dunselman G.A.J., Bouma-Ter Steege J.C.A., Thijssen V.L.J.L., Evers J.L.H., Groothuis P.G. Antiangiogenesis therapy for endometriosis. J. Clin. Endocrinol. Metab. 2004, 89:1089-1095.
92. Naumann U., Cameroni E., Pruenster M., Mahabaleshwar H., Raz E., Zerwes H.G., Rot A., Thelen M. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS ONE 2010, 5:e9175.
93. Nesselroth S.M., Willis A.I., Fuse S., Olson E.T., Lawler J., Sumpio B.E., Gahtan V. The C-terminal domain of thrombospondin-1 induces vascular smooth muscle cell chemotaxis. J. Vasc. Surg. 2001, 33:595-600.
94. Nisolle M., Casanas-Roux F., Anaf V., Mine J.M., Donnez J. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil. Steril. 1993, 59:681.
95. Nnoaham K.E., Hummelshoj L., Webster P., d'Hooghe T., de Cicco Nardone F., de Cicco Nardone C., Jenkinson C., Kennedy S.H., Zondervan K.T. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil. Steril. 2011, 96. 366-373e8.
96. Olivares C., Ricci A., Bilotas M., Barañao R.I., Meresman G. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil. Steril. 2011.
97. Otrock Z.K., Mahfouz R.A., Makarem J.A., Shamseddine A.I. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol. Dis. 2007, 39:212-220.
98. Ozawa Y., Murakami T., Tamura M., Terada Y., Yaegashi N., Okamura K. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice. Fertil. Steril. 2006, 86:1146-1151.
99. Petit I., Jin D., Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 2007, 28:299-307.
100. Punekar S., Zak S., Kalter V.G., Dobransky L., Punekar I., Lawler J.W., Gutierrez L.S. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology 2008, 75:9-21.
101. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 2000, 105:17-19.
102. Rafii S., Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 2003, 9:702-712.
103. Rehman J., Li J., Orschell C.M., March K.L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003, 107:1164-1169.
104. Reyes M., Dudek A., Jahagirdar B., Koodie L., Marker P.H., Verfaillie C.M. Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 2002, 109:337-346.
105. Ricci A.G., Olivares C.N., Bilotas M.A., Meresman G.F., Baranao R.I. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reprod. Sci. 2011, 18:614-622.
106. Sampson J.A. Peritoneal endometriosis due to menstrual dissemination of endometrial tissue. Am. J. Obstet. Gynecol. 1927, 14:422-469.
107. Simoens S., Hummelshoj L., D'Hooghe T. Endometriosis: cost estimates and methodological perspective. Hum. Reprod. Update 2007, 13:395-404.
108. Somigliana E., Vigano P., Rossi G., Carinelli S., Vignali M., Panina-Bordignon P. Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum. Reprod. 1999, 14:2944-2950.
109. Tan X.J., Lang J.H., Liu D.Y., Shen K., Leng J.H., Zhu L. Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis. Fertil. Steril. 2002, 78:148-153.
110. Thaunat O., Louedec L., Graff-Dubois S., Dai J., Groyer E., Yacoub-Youssef H., Mandet C., Bruneval P., Kaveri S., Caligiuri G. Antiangiogenic treatment prevents adventitial constrictive remodeling in graft arteriosclerosis. Transplantation 2008, 85:281.
111. Urbich C., Dimmeler S. Endothelial progenitor cells functional characterization. Trends Cardiovasc. Med. 2004, 14:318-322.
112. Virani, S., 2011. Role of Stromal Cell-derived Factor-1 in Neoangiogenesis in Endometriosis Lesions. Queen's University, Dept. of Biomedical and Molecular Sciences.
113. Volpert O.V., Zaichuk T., Zhou W., Reiher F., Ferguson T.A., Stuart P.M., Amin M., Bouck N.P. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat. Med. 2002, 8:349-357.
114. Xu Z., Zhao F., Lin F., Chen J., Huang Y. Lipoxin A4 inhibits the development of endometriosis in mice: the role of anti-inflammation and anti-angiogenesis. Am. J. Reprod. Immunol. 2012.
115. Xu H., Lui W.T., Chu C.Y., Ng P.S., Wang C.C., Rogers M.S. Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model. Hum. Reprod. 2009, 24:608-618.